Label-retaining liver cancer cells are relatively resistant to sorafenib

Gut

Volumn 62, Issue 12, 2013, Pages 1777-1786

  Xin, Hong Wu ^a   Ambe, Chenwi M ^a   Hari, Danielle M ^a   Wiegand, Gordon W ^a   Miller, Tyler C ^a   Chen, Jin Qiu ^a   Anderson, Andrew J ^a   Ray, Satyajit ^a   Mullinax, John E ^a   Koizumi, Tomotake ^a   Langan, Russell C ^a   Burka, Douglas ^a   Herrmann, Michelle A ^a   Goldsmith, Paul K ^a   Stojadinovic, Alexander ^b,c   Rudloff, Udo ^a   Thorgeirsson, Snorri S ^a   Avital, Itzhak ^a,c,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^d Bon Secours Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SORAFENIB; WNT PROTEIN;

ALDEHYDE DEHYDROGENASE 1 FAMILY A1 GENE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LABEL RETAINING CANCER CELL; LIVER CELL CARCINOMA; MARKER GENE; PRIORITY JOURNAL; UPREGULATION; WINGLESS TYPE MMTV INTEGRATION SITE FAMILY GENE;

CANCER; CELL PROLIFERATION; DRUG RESISTANCE; HEPATOCELLULAR CARCINOMA; STEM CELLS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; ONCOGENE PROTEIN V-AKT; PHENYLUREA COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; STEM CELLS;

EID: 84887458286     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303261     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
3. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44.
4. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
5. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev 2008;8:755-68.
6. Capper D, Gaiser T, Hartmann C, et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol 2009;117:445-56.
7. Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011;121:396-409.
8. Smith GH. Label-retaining epithelial cells in mouse mammary gland divide asymmetrically and retain their template DNA strands. Development 2005;132:681-7.
9. Kuwahara R, Kofman AV, Landis CS, et al. The hepatic stem cell niche: identification by label-retaining cell assay. Hepatology 2008;47:1994-2002.
10. Hari D, Xin HW, Jaiswal K, et al. Isolation of live label-retaining cells and cells undergoing asymmetric cell division via nonrandom chromosomal cosegregation from human cancers. Stem Cells Dev 2011;20:1649-58.
11. Xin HW, Hari DM, Mullinax JE, et al. Tumor initiating label-retaining-cancer-cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 2012;30:591-8.
12. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40.
13. Gedaly R, Angulo P, Hundley J, et al. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 2010;30:4951-8.
14. Rosato RR, Almenara JA, Coe S, et al. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007;67:9490-500.
15. Rausch V, Liu L, Kallifatidis G, et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 2010;70:5004-13.
16. Park MA, Zhang G, Martin AP, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008;7:1648-62.
17. Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 2006;319:1070-80.
18. Thompson B, Townsley F, Rosin-Arbesfeld R, et al. A new nuclear component of the Wnt signalling pathway. Nat Cell Biol 2002;4:367-73.
19. Binet R, Ythier D, Robles AI, et al. WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2009;69:9183-91.
20. Abdul-Ghani M, Megeney LA. Rehabilitation of a contract killer: caspase-3 directs stem cell differentiation. Cell Stem Cell 2008;2:515-16.
21. Panka DJ, Wang W, Atkins MB, et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006;66:1611-19.
22. Chen KF, Chen HL, Tai WT, et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2011;337:155-61.